Bajaj Healthcare Share Price in Focus on Acquisition of GenRx for ₹10.85 Crore

Bajaj Healthcare Limited (BHL), on April 7, 2025, announced the acquisition of GenRx Pharmaceuticals Private Limited for ₹10.85 crore in cash. The deal involves 100% control of the target company and will be completed over the next 3-6 months, subject to regulatory approvals, including those from the FDA.

About GenRx Pharmaceuticals

GenRx Pharmaceuticals was incorporated in 2009 and is headquartered in Thane, Maharashtra. The company operates a manufacturing facility at MIDC Sinnar in Nashik. It holds a WHO-GMP certification and is involved in the production of allopathic formulations, nutraceuticals, and natural products. Its facility is equipped to produce solid and semi-solid dosage forms, including tablets, capsules, nasal sprays, cosmetic products, and external preparations.

“The acquisition of GenRx Pharmaceuticals marks a strategic step forward in expanding our formulations manufacturing capabilities. This aligns with our vision of strengthening our core business and leveraging synergies for accelerated growth,” said Anil Jain, Managing Director of Bajaj Healthcare.

“This addition will enable us to expand our manufacturing portfolio, paving the way for long-term value creation and strengthening our footprint in the pharmaceutical sector,” Jain added.

Financial Overview

In Q3 FY25, Bajaj Healthcare reported a net profit of ₹11.7 crore, compared to a net loss of ₹2.2 crore in Q3 FY24. Revenue from operations stood at ₹122.8 crore, marking a 13.1% increase year-on-year. EBITDA rose to ₹21.7 crore from ₹19.6 crore, while the EBITDA margin slightly decreased to 17.7% from 18.1%.

Share Price Performance

As of 10:55 AM on April 8, 2025, Bajaj Healthcare share price was trading at ₹578.10, up 1.55% and up 53.33% over the past six months and 77.35% over the past year. The company’s market capitalisation stood at ₹1,800.25 crore. Additionally, the company’s CFO, Dayashankar Patel, resigned last week, citing personal reasons.

Conclusion

The deal is currently pending regulatory approvals and is expected to close in the coming months.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.